CVS and Walgreens to start selling abortion pill mifepristone this month 

CVS and Walgreens to start selling abortion pill mifepristone this month 


A container holding boxes of mifepristone, the first medication in a medical abortion, are prepared for patients at Alamo Women’s Clinic in Carbondale, Illinois, on April 20, 2023.

Evelyn Hockstein | Reuters

CVS and Walgreens will start selling the abortion pill mifepristone this month at certain pharmacy locations in states where it is legal to do so, spokespeople for the companies told CNBC on Friday. 

CVS and Walgreens received certification from the Food and Drug Administration to dispense the commonly used pill at their retail pharmacies, spokespeople for each company said in separate statements.

CVS will begin filling prescriptions for the medication in Massachusetts and Rhode Island in the coming weeks, a spokesperson for the company said. They added that CVS will expand to additional states, “where allowed by law, on a rolling basis.” 

Walgreens expects to start dispensing prescriptions for the pill within a week at select pharmacy locations in New York, Pennsylvania, Massachusetts, California, and Illinois, a company spokesperson said.

Notably, the chains will not provide the medication by mail. The New York Times reported the news earlier Friday.

Mifepristone is the first pill used in the two-drug medication abortion regimen.

The FDA is squaring off with anti-abortion physicians in an unprecedented legal challenge to its more than two decade-old approval of mifepristone. An anti-abortion rights group sued the agency in 2022 in a bid to declare that approval unlawful and completely remove the pill from the U.S. market

On March 26, the Supreme Court will hear oral arguments in that closely watched case.

The Food and Drug Administration in January said that it will allow retail pharmacies to offer mifepristone in the U.S. for the first time. 

Under a regulatory change at the agency, pharmacies can apply for certification to distribute the pill with one of the two companies that make it. That certification would allow pharmacies to dispense the medication directly to patients upon receiving a prescription from a certified prescriber.

Before the FDA’s regulatory change, only a few mail-order pharmacies or specially certified doctors or clinics could distribute mifepristone.

The regulatory change will potentially expand abortion access as the Biden administration wrestles with how best to protect abortion rights. The right to abortion in the U.S. was sharply curtailed by the Supreme Court’s 2022 decision to overturn the landmark Roe v. Wade ruling.

The Biden administration has sought to make abortion and contraception access a main platform of the president’s 2024 campaign.

Medication abortion is the most common method of terminating a pregnancy in the U.S., according to data from the Centers for Disease Control and Prevention. That method is approved by the FDA for use up to 10 weeks into pregnancy.



Source

RFK Jr. announces new nutrition guidelines, pushing more protein and less processed food
Health

RFK Jr. announces new nutrition guidelines, pushing more protein and less processed food

Secretary of Health and Human Services Robert F. Kennedy Jr. speaks during the daily briefing in the Brady Briefing Room of the White House in Washington, DC, on Jan. 7, 2026. Mandel Ngan | AFP | Getty Images Health and Human Services Secretary Robert F. Kennedy Jr. and Agriculture Secretary Brooke Rollins on Wednesday shared […]

Read More
First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. 
Health

First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. 

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Nov. 24, 2025. Tom Little | Reuters Novo Nordisk will start rolling out the first-ever GLP-1 pill for weight loss in the U.S. on Monday, the company announced, marking a new chapter of obesity […]

Read More
2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit
Health

2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit

The ripple is about to become a wave. Right now, there are numerous barriers for people who are considering treating their obesity with GLP-1 drugs. Early on, there were manufacturing bottlenecks that resulted in short supplies of Novo Nordisk ‘s Wegovy and Eli Lilly ‘s Zepbound. There were insurance coverage issues for these pricey treatments, […]

Read More